About Apoptosis-enhancing nuclease
Apoptosis-enhancing nuclease (AEN) is a protein
from Homo sapiens identified by UniProt accession
Q8WTP8, 325 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Apoptosis-enhancing nuclease |
|---|
| UniProt accession | Q8WTP8 |
|---|
| Gene | AEN |
|---|
| Organism | Homo sapiens |
|---|
| Length | 325 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (34)
Diseases linked to this target (Open Targets).
- retinal nerve fibre layer thickness measurement · score 0.20
- macula measurement · score 0.19
- retinal layer thickness measurement · score 0.19
- insulin like growth factor measurement · score 0.17
- IGF-1 measurement · score 0.16
- age-related hearing impairment · score 0.15
- hormone measurement · score 0.13
- thyroid stimulating hormone measurement · score 0.13
- sitting height measurement · score 0.13
- Dupuytren Contracture · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8WTP8-F1 | alphafold | PREDICTED | 74.29 | — |
Amino-acid sequence (325 residues)
MVPREAPESA QCLCPSLTIP NAKDVLRKRH KRRSRQHQRF MARKALLQEQ GLLSMPPEPG SSPLPTPFGA ATATEAASSG KQCLRAGSGS APCSRRPAPG KASGPLPSKC VAIDCEMVGT GPRGRVSELA RCSIVSYHGN VLYDKYIRPE MPIADYRTRW SGITRQHMRK AVPFQVAQKE ILKLLKGKVV VGHALHNDFQ ALKYVHPRSQ TRDTTYVPNF LSEPGLHTRA RVSLKDLALQ LLHKKIQVGQ HGHSSVEDAT TAMELYRLVE VQWEQQEARS LWTCPEDREP DSSTDMEQYM EDQYWPDDLA HGSRGGAREA QDRRN
Explore Apoptosis-enhancing nuclease with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets